France has entered a new phase in its public discussion on vaping. A comprehensive scientific assessment by Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail (ANSES) is reshaping how policymakers approach e-cigarette regulation.
Completed in December 2025 and officially published on February 4, 2026, the 700-page report concludes that e-cigarettes present a lower overall health risk than combustible tobacco. At the same time, ANSES stresses that vaping is not risk-free. The report’s release coincided with the French government’s decision to withdraw a proposed excise tax on e-liquids from the 2026 Finance Bill, creating a clear alignment between scientific evaluation and fiscal policy timing.
ANSES and HAS: Distinct Roles in France’s Regulatory Framework
ANSES operates under France’s Ministry of Health as an independent national risk assessment body. Its mandate is to provide scientific evidence to inform public policy.
This function differs from that of Haute Autorité de Santé (HAS), which develops clinical and public health guidelines. HAS is expected to issue recommendations in 2026 regarding whether and how e-cigarettes should be integrated into official smoking cessation strategies.
Together, ANSES and HAS form the scientific and clinical backbone of France’s nicotine product governance system.
Core Conclusion: Lower Risk Than Smoking, But Not Harmless
ANSES does not advocate banning e-cigarettes. Instead, it confirms the existence of a “relative risk differential” between vaping and combustible cigarettes.
Because e-cigarettes do not involve combustion, exposure to many toxic substances is significantly reduced compared with cigarette smoke. In modeling focused on aldehyde exposure, ANSES found that emissions from e-cigarettes may be reduced by roughly 80% to near-total reduction in certain scenarios when compared with combustible tobacco.
However, reduced emissions do not equate to zero health risk. That distinction is central to the report.
Identified Health Risks and Scientific Uncertainty
After reviewing thousands of epidemiological and experimental studies, ANSES identified several potential health concerns:
- Possible cardiovascular effects in nicotine-containing products
- Potential respiratory and carcinogenic risks (with or without nicotine)
- Possible impacts on fetal cardiovascular and respiratory development during prenatal exposure
- Significant scientific uncertainty regarding long-term health outcomes
Importantly, ANSES emphasizes that neither the severity of risk nor the strength of evidence exceeds the well-established risks associated with combustible cigarettes. The absence of combustion remains the key differentiator between the two product categories.
Methodology: Dual-Track Risk Assessment
ANSES adopted a structured “dual assessment” model:
- Évaluation des risques sanitaires (ERS) – A systematic literature review of epidemiological and laboratory research
- Évaluation quantitative des risques sanitaires (EQRS) – A quantitative risk modeling approach, with a particular focus on aldehyde exposure during vaping
This combined framework strengthens the credibility of the conclusions by integrating both qualitative evidence and quantitative exposure modeling.
A Harm Reduction Tool Primarily Used by Smokers
One important contextual finding: among adult e-cigarette users in France, the overwhelming majority are current or former smokers. Only around 2% have never smoked.
This reality complicates efforts to isolate the independent effects of vaping from the health consequences of prior tobacco use. It also reinforces the prevailing policy narrative: in France, e-cigarettes are primarily viewed as harm reduction tools for smokers rather than entry products for non-smokers.
Ingredient Control and Emerging Nicotine Compounds
Beyond toxicology, ANSES gives considerable attention to addiction mechanisms and product appeal.
The report recommends the establishment of a formal “negative list” of prohibited e-liquid ingredients. It specifically mentions compounds such as nornicotine and 6-methyl-nicotine, signaling increased scrutiny of novel nicotine-related substances.
ANSES also calls for ongoing monitoring of technological innovations, including nicotine salts and high-efficiency delivery systems. These technologies may alter nicotine absorption patterns and potentially influence addiction dynamics and youth attractiveness.
DIY E-Liquid Mixing: A Regulatory Blind Spot
Another notable finding concerns “DIY” e-liquid mixing. According to survey data cited by ANSES, approximately half of adult vapers report mixing their own e-liquids.
While this practice can reduce costs and increase customization, it introduces regulatory challenges. Users may combine nicotine base liquids with flavorings not specifically designed for inhalation. Improper ratios or unsuitable ingredients could create additional health risks outside standardized manufacturing controls.
ANSES recommends enhanced market monitoring and clearer consumer information to address these risks.
Taxation: Proceed with Caution
On fiscal policy, ANSES advises that any future excise tax on e-liquids should remain moderate. Excessive taxation could stimulate illicit trade or unsafe informal production—outcomes that would undermine public health objectives.
Future Research: Toward Biomarker-Based Assessment
Looking ahead, ANSES highlights the need for standardized research methodologies. Beyond traditional aerosol and emissions analysis, future studies may increasingly rely on biomarker measurements—such as metabolites detected in blood or urine—to assess long-term exposure more accurately.
This shift would improve comparability across studies and enhance the policy relevance of scientific findings.
Broader Implications for the EU and Global Industry
As one of the European Union’s major nicotine markets, France’s regulatory trajectory carries broader significance. The ANSES report signals a mature regulatory approach: acknowledging harm reduction potential while strengthening product governance.
The policy debate is no longer centered on whether vaping is less harmful than smoking. That relative difference is largely recognized. The real question now is how to manage vaping risks within increasingly sophisticated regulatory frameworks.
For international brands, regulators, and supply chain stakeholders, the French case offers a clear message: future success in the European market will depend not only on product performance, but on compliance, transparency, and adaptability in a science-driven regulatory environment.
Leave a Reply